ARTICLE SUMMARY:
Gender-specific therapies improve both patient care and ROI for investors and developers, but necessary data isn't being collected today. The phased-in elimination of the inpatient-only rule and the migration of procedures to ASCs are forcing medtechs to rethink where and how much they get paid; Common mistakes that kill start-ups; Can a disciplined screening criteria improve angel investing outcomes? Plus profiles of Argá Medtech, Nephrodite, and SleepRes.
